“The findings did not surprise us, but supported our hypothesis that patients with UC have reduced compliance of their rectum, even when they are in remission,” Dr. Rubin told Reuters Health by email. “The exciting new finding is that those who normalized their histology – i.e., biopsies show no evidence of chronic colitis – had compliance similar to the non-colitis control group.”
Click here to listen to Dr. Rubin speak with colleagues and IBD Drive Time hosts Raymond Cross, MD and Millie Long, MD on using newly-approved ozanimod in treating ulcerative colitis.
Click here for the full video discussing the use of COVID-19 vaccines to prevent COVID-19 infections in patients with inflammatory bowel disease.
Click here for the full video of Drs. Rubin, Siegel, Melmed, and Horrigan discussing the safety and efficacy of COVID-19 vaccines for patients with inflammatory bowel disease.
Dr. Rubin Discusses Advances in Anti-Cytokine Therapy: The Current and Potential Role of IL-12/23 and IL-23 Inhibitors in the Treatment of IBD
Click here to watch Dr. Rubin discuss the advances in anti-cytokine therapy and receive AANP, AAPA, CME, CNE, CPE, or participation credit.
Watch this video exclusive, to hear David T. Rubin, MD highlight how the COVID-19 pandemic changed the use of social media.
Click here to watch Dr. David Rubin and his colleagues explain the data behind the various vaccines, clinical recommendations, allergy and safety recommendation, and describe COVID-19 vaccine special issues in underrepresented minorities.
Click here to watch Dr. Rubin and Dr. Long review the role of cell trafficking in IBD pathogenesis and how therapies that modulate immune cell trafficking compare with other agents that target the inflammatory response in IBD.